
Former Merck R&D expert joins RedX Pharma board
pharmafile | January 4, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | RedX Pharma
Dr Bernhard Kirschbaum, 57, has been added as a non-executive director at RedX Pharma with immediate effect.
Kirschbaum is a former Merck research and drug development specialist at US pharma giant Merck/Merck Serono, becoming a member of the board of Merck Serono and executive vice-president of global research & early development.
In his last three years, he grew the company’s research and development department, doubling the number of phase II assets in this period.
During his career, he has held roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel.
Neil Murray, chief executive of UK-based Redx, says: “He has an outstanding track record and I have no doubt that Redx will benefit from his significant commercial and scientific expertise.”
Redx is focused on improving the characteristics of existing drug classes to create what it hopes are highly effective new medicines.
Related Content

Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma
Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement …






